A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Phase of Trial: Phase III
Latest Information Update: 15 Apr 2018
At a glance
- Drugs Rigosertib (Primary)
- Indications Myelodysplastic syndromes
- Focus Registrational; Therapeutic Use
- Acronyms INSPIRE
- Sponsors Onconova Therapeutics
- 08 Mar 2018 According to an Onconova Therapeutics media release, more than half of the expanded study is now enrolled. The Company is planning to add sites in Europe and new territories, including in Latin America, in concert with Pint Pharma.
- 05 Mar 2018 According to an Onconova Therapeutics media release, top-line data expected in 2019.
- 12 Feb 2018 According to an Onconova Therapeutics media release, certain topline results anticipated on the one-month anniversary of the date.